Clinical Trial Update: Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating tipifarnib and fulvestrant in hormone receptor-positive metastatic breast cancer has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-08-10